- Report
- January 2026
- 191 Pages
Global
From €3447EUR$3,939USD£2,997GBP
- Report
- January 2026
Global
From €4288EUR$4,900USD£3,728GBP
- Report
- January 2026
Global
From €4288EUR$4,900USD£3,728GBP
- Report
- September 2025
- 250 Pages
Global
From €3930EUR$4,490USD£3,416GBP
- Report
- September 2025
- 250 Pages
Global
From €3930EUR$4,490USD£3,416GBP
- Report
- July 2025
- 175 Pages
Global
From €3930EUR$4,490USD£3,416GBP
- Report
- July 2025
- 175 Pages
Global
From €3930EUR$4,490USD£3,416GBP
- Report
- July 2025
- 175 Pages
Global
From €3930EUR$4,490USD£3,416GBP
- Report
- February 2025
- 200 Pages
Global
From €3930EUR$4,490USD£3,416GBP
- Report
- February 2026
- 372 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 386 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 361 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 384 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 588 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 179 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 477 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 326 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 194 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- February 2026
- 482 Pages
Global
From €5120EUR$5,850USD£4,451GBP
- Report
- January 2026
- 195 Pages
Global
From €3447EUR$3,939USD£2,997GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more